MetaCap

IQVIA Holdings Inc. (IQV)

NYSE: IQVHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

245.82-4.73 (-1.89%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IQV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$40.51B
52-week range
154.50 – 284.50
Day range
245.25 – 252.28
Volume / Avg
1.25M / 1.45M
Beta
—

52-week range

$154.50$284.50

IQV stock today

On Nov 20, IQV ended the session at $245.82, shedding $4.73 (1.89%), versus the S&P 500's 3.70% decline. At this level, IQV sits in the middle of its 52-week range of $154.50 to $284.50: 13.6% below the high, set on Oct 27, 2026 and 59.1% above the low. IQV is up 9.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 9.3%.

At 29.9x trailing earnings, IQVIA trades below the peer-group median of 66.6x. Its forward P/E of 17.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About IQVIA

Company profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Mr. Ari Bousbib
Headquarters
Durham, NC
Employees
95,000
IPO year
2013
Website
iqvia.com

Financial highlights

Full financials

In fiscal 2025, IQVIA generated $16.31 billion in revenue, up 5.9% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $1.36 billion (-0.9% year over year), for a net margin of 8.3% versus a median of 7.6% in the prior 5 years. Gross margin was 33.3% (down from 34.9%) and operating margin 13.4%.

IQVIA annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$16.31B$15.40B$14.98B$14.41B$13.87B
Growth+5.87%+2.81%+3.98%+3.86%+22.14%
Net income$1.36B$1.37B$1.36B$1.09B$966.00M
EPS (diluted)$7.84$7.49$7.29$5.72$4.95

Analyst forecast

Forecast

Consensus (20 analysts)

none

Avg. price target

$311.89+26.88%

  • Strong buy 2
  • Buy 16
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $268.00High $346.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$2.10 vs $2.94
Surprise
-28.57%

IQV news

All IQV news

IQVIA peers

Health Care sector
IQV peer companies
CompanyPrice% ChgMarket capCompare
INCYIncyte Corp.114.63-1.07%$23.36Bvs IQV
MEDPMedpace Holdings Inc.610.54-3.70%$17.08Bvs IQV
CRLCharles River Laboratories International Inc.314.32-4.15%$15.06Bvs IQV
ICLRICON plc186.71-1.92%$13.99Bvs IQV
ABSIAbsci Corporation7.51-7.97%$1.30Bvs IQV
OABIOmniAb Inc.4.66-7.36%$679.71Mvs IQV
NRCNRC Health25.16+0.68%$533.93Mvs IQV
MXCTMaxCyte Inc.1.37+7.03%$141.45Mvs IQV

Indexes, lists and sector

IQVIA stock FAQ

What is IQVIA's stock price today?

IQV last traded at $245.82 as of Nov 20, 4:00 PM EST, down 1.89% on the day. Prices are delayed at least 15 minutes.

What is IQV's P/E ratio?

IQV trades at a trailing P/E ratio of 29.91 and a forward P/E of 17.31, compared with a median of 66.6 for its closest peers.

Is IQVIA in the S&P 500?

Yes. IQVIA (IQV) is a constituent of the S&P 500 index.

Who is IQVIA's CEO?

Mr. Ari Bousbib is the chief executive officer of IQVIA Holdings Inc., which has about 95,000 employees.

What is the IQV 52-week high?

The 52-week high for IQV is $284.50 and the 52-week low is $154.50. The stock is currently 13.6% below its high.

Compare IQV